Drug Profile
AD 2011
Alternative Names: AD-2011Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Addpharma
- Class Antihyperlipidaemics; Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Hyperlipidaemia; Hypertension
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for phase-I development in Hyperlipidaemia(Combination therapy, In volunteers) in South Korea (PO, Tablet)
- 28 Jul 2021 No recent reports of development identified for phase-I development in Hyperlipidaemia(Monotherapy, In volunteers) in South Korea (PO, Tablet)
- 28 Jul 2021 No recent reports of development identified for phase-I development in Hypertension(Combination therapy, In volunteers) in South Korea (PO, Tablet)